Posters

      A Multicenter, Multiregional Study on Biological and Functional Changes in Healthy Adult Smokers During One Year of Continuous Smoking Abstinence

      Felber Medlin , L.; Tran, C. T.; Ng, W. T.; Lama, N.; Taranu, B.; Pierri, E.; Picavet, P.; Baker, G.; Haziza, C.; Lüdicke, F.
      Conference date
      Feb 22, 2019
      Conference name

      Society for Research on Nicotine and Tobacco (SRNT) 2019
      Link to more information
      Topic
      Summary

      Background: The harm from smoking results mainly from long-term exposure to harmful and potentially harmful constituents (HPHC) in cigarette smoke generated by the combustion of tobacco. Smoking cessation (SC) is the most effective way to reduce the harm and risk of smoking-related diseases. In most SC studies, the main focus is on the rate of successful quitting for the SC approach/treatment tested; only limited information on multiple short- to long-term functional/ biological changes following SC is available in the literature. The overall study aim was to assess, over a one-year period of continuous smoking abstinence, the reversibility of the harm caused by smoking by assessing changes in clinical risk endpoints (CRE) linked to the pathophysiological pathways underlying the development of smoking-related diseases. Methods: This was a multicenter (42 sites), multiregional (U.S., Europe, Japan) SC study in healthy adult smokers planning to quit smoking within the next 30 days who were asked to continuously abstain from smoking during a one-year period in an ambulatory setting. Results: The study enrolled 1184 subjects (50.1% male), with 30% having successfully quit smoking for one year. The study showed favorable changes in several CREs linked to cardiovascular diseases (CVD), as indicated by a decrease from baseline in WBC, 11-DTX-B2, 8-epi-PGF2α, and sICAM-1; a slight decrease in homocysteine and fibrinogen; and a slight increase in HDL-C. For some other CREs associated with CVD (Apo A1 and B, LDL-C, hs-CRP, platelets, Albumin, and HbA1c) and respiratory functions, no major changes from baseline were observed after one year of smoking abstinence. Levels of all the biomarkers of exposure to HPHCs, including COHb and Total NNAL, were substantially reduced, ranging from –54.5% to –97.9%. Conclusions: These results indicate that continuous abstinence from smoking for one year leads to a substantial reduction in exposure to HPHCs and favorable changes in multiple mechanistic pathways and biological functions, such as lipid metabolism, inflammation, or oxidative stress, that are likely to contribute to the reduction of risk of developing smoking-related diseases.

      Related Publications

      Comparison of Abdominal Aortic Aneurysm Growth in Adult Smoking Patients Who Either Switch to IQOS, Continue Smoking, or Quit Smoking

      Clinical

      Systematic review of the relation between smokeless tobacco and cancer of the pancreas in Europe and North America

      Clinical

      Reduced exposure to Harmful and Potentially Harmful Constituents after 90 days of use of Tobacco Heating System 2.2 Menthol in Japan: A comparison with continued cigarette use or smoking abstinence

      Clinical

      Reduced Exposure To Harmful And Potentially Harmful Constituents after 90 Days Of Use Of Tobacco Heating System 2.2 Menthol In Japan: A Comparison With Continued Cigarette Use Or Smoking Abstinence

      Clinical

      Psychometric Evaluation of the mCEQ applied to Cigarettes and Heat-Not-Burn Products in the US and Japan

      Clinical

      Pharmacokinetics Of Nicotine And Subjective Effects Following The Single Use Of A Non-Menthol And Menthol Version Of Tobacco Heating System 2.2 In Two Studies In Japan: A Comparison With Single Use Of A Combustible Cigarette And Nicotine Gum

      Clinical

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.